

# Immune response and protection assay of recombinant major surface glycoprotein of *Leishmania* (rgp<sup>13</sup>) reconstituted with liposomes in BALB/c mice

**Author(s):** Jaafari, MR (Jaafari, Mahmoud R.); Ghafarian, A (Ghafarian, Attieh); Farrokh-Gisour, A (Farrokh-Gisour, Ahsan); Samiei, A (Samiei, Afshin); Kheiri, MT (Kheiri, Masoumeh Tavassoti); Mahboudi, F (Mahboudi, Fereidoun); Barkhordari, F (Barkhordari, Farzaneh); Khamesipour, A (Khamesipour, Ali); McMaster, WR (McMaster, W. Robert)

**Source:** VACCINE **Volume:** 24 **Issue:** 29-30 **Pages:** 5708-5717 **DOI:** 10.1016/j.vaccine.2006.04.062  
**Published:** JUL 17 2006

**Times Cited:** 27 (from Web of Science)

**Cited References:** 27 [ [view related records](#) ]  [Citation Map](#)

**Abstract:** In this study the ability of recombinant gp<sup>13</sup> entrapped in liposomes to induce immune response and protection against L. major infection in susceptible BALB/c mice was studied. Liposomes containing rgp<sup>13</sup> (Lip-rgp<sup>13</sup>) were prepared from egg lecithin and cholesterol using detergent solubilization method. Immunization of BALB/c mice with rgp<sup>13</sup> alone conferred a partial protection while entrapment of rgp<sup>13</sup> in liposomes significantly increased the rate of protection ( $P < 0.05$ ). The parasite burden of spleen in mice challenged with L. major was significantly ( $p < 0.001$ ) lower in group of mice immunized with rgp<sup>13</sup> alone or Lip-rgp<sup>13</sup>, however, the least parasite burden was seen in Lip-rgp<sup>13</sup> group. Both rgp<sup>13</sup> alone and Lip-rgp<sup>13</sup> elicited significant delayed-type hypersensitivity (DTH) response compared to controls ( $p < 0.01$ ), however, the DTH response of PBS-rgp<sup>13</sup> was less than the Lip-rgp<sup>13</sup>. Titration of anti-*Leishmania* IgG isotypes (IgG<sup>2a</sup>/IgG<sup>1</sup>) showed a preferential Th<sub>1</sub> type of immune response only in mice immunized with Lip-rgp<sup>13</sup>. The results indicate that liposomes might be used as a suitable immunoadjuvant for development of *Leishmania* vaccine. (c) 2006 Elsevier Ltd. All rights reserved.

**Accession Number:** WOS:000239081600007

**Document Type:** Article

**Language:** English

**Author Keywords:** liposomes; rgp<sup>13</sup>; cutaneous leishmaniasis

**KeyWords Plus:** MURINE CUTANEOUS LEISHMANIASIS; VACCINE PLUS BCG; VISCERAL LEISHMANIASIS; AMAZONENSIS VACCINE; ANTIGEN-LIPOSOMES; CHARGED LIPOSOMES; INTERFERON-GAMMA; CONTROLLED-TRIAL; DOUBLE-BLIND; FIELD TRIAL

**Reprint Address:** Jaafari, MR (reprint author), Mashhad Univ Med Sci, Sch Pharm, Biotechnol Res Ctr, POB 91177-1360, Mashhad, Iran.

## Addresses:

1. Mashhad Univ Med Sci, Sch Pharm, Biotechnol Res Ctr, Mashhad, Iran
2. Mashhad Univ Med Sci, Sch Pharm, Pharmaceut Res Ctr, Mashhad, Iran
3. Pasteur Inst Iran, Biotechnol Res Ctr, Tehran, Iran
4. Univ Tehran Med Sci, Ctr Res & Training Skin Dis & Leprosy, Tehran, Iran
5. Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada

**E-mail Address:** [mr\\_jaafari@yahoo.com](mailto:mr_jaafari@yahoo.com)

**Publisher:** ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND

**Web of Science Categories:** Immunology; Medicine, Research & Experimental

**Research Areas:** Immunology; Research & Experimental Medicine

**IDS Number:** 064IE

**ISSN:** 0264-310X